The company was valued at approximately NOK 1,350 million and shares for an amount of NOK 575 million were sold in the IPO. Nordic Nanovector ASA’s mission is to develop and commercialize innovative radioimmunotherapeutics that target difficult to treat cancers using the company’s proprietary nanovector targeting technology. The company’s lead product candidate, BetalutinTM aims to prolong the survival and improve the quality of life of patients who suffer from non-Hodgkin Lymphoma (NHL).

Thommessen was the company’s legal advisor in the IPO. Managers for the IPO were ABG Sundal Collier, Carnegie and DNB Markets.

Please follow this link in order to read Nordic Nanovector ASA’s press announcement.